Skip to content

Accelerated Aging in Middle-Aged Men With Sleep-disordered Breathing.

Accelerated Aging in Middle-Aged Men With Sleep-disordered Breathing.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02876653
Acronym
SAOS
Enrollment
53
Registered
2016-08-24
Start date
2011-03-31
Completion date
2014-01-31
Last updated
2016-08-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obstructive Sleep Apnea

Keywords

Obstructive sleep apnea, Aging, Telomere length

Brief summary

Obstructive Sleep Apnea Syndrome (OSAS) regardless of any other associated risk factor can lead to accelerated aging. The study of aging-related Obstructive Sleep Apnea (OSA) is difficult because of associated risk factors (diabetes, hypertension, dyslipidemia, obesity), promoting themselves aging. The investigators propose to compare a group of OSAS patients free of any associated pathology, to subjects matched for age, sex, smoking and body mass index (BMI)

Interventions

OTHERPolysomnography , blood collection, bone densitometry and Functional respiratory explorations

Blood collection, Bone densitometry and Functional respiratory explorations are a specific interventions of protocol for the 3 arms. Polysomnography is a specific intervention for the arms healthy volunteers

Sponsors

Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
20 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

Patient: * Men aged 20 to 65 years * Having polysomnography in the Functional Explorations department, Sleep Laboratory, Hospital Henri Mondor, Creteil * With an AHI \> 5 / h Healthy volunteers: * Men aged 20 to 65 years * With an AHI ≤ 5 / h

Exclusion criteria

All subjects: * Known cardiovascular risk: hypertension treated, diabetes treated, dyslipidemia treated, * Known cardiovascular disease associated (heart failure, rhythm disorder ...) * Known respiratory diseases * Known neoplastic pathology, known chronic inflammatory disease * Psychiatric pathology treated * Medication * Not affiliated to the French social health care system * Major protected person * Private person of liberty * People in emergency situation * Patient refusing to participate in the study

Design outcomes

Primary

MeasureTime frame
Telomere length of circulating leukocytes4 weeks

Secondary

MeasureTime frame
Bone density4 weeks
Correlation between biological parameters and neuropsychological assessment4 weeks
Carotid-femoral pulse wave velocity4 weeks
Markers of inflammation: hs-CRP, IL-6, IL-8, MCP-14 weeks
Markers of growth hormone axis (GH, IGF-1, IGFBP)4 weeks
Markers of oxidative stress: Malondialdehyde, heme oxygenase-14 weeks

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026